HGH Fragment 176-191
Also known as: AOD9604, hGH 176-191, GH fragment 176-191
Growth hormone (GH) C-terminal fragment / synthetic peptide
What it is
HGH Fragment 176-191 is a fragment of growth hormone that people use for fat loss, believed to retain the fat-burning properties of GH without affecting blood sugar. Evidence from animal studies is modest; human research is very limited. Not FDA-approved; gray-market research compound; regulatory status unverified.
The scientific side
HGH Fragment 176-191 corresponds to amino acids 176–191 of the C-terminal region of human growth hormone. Early animal research (1978) demonstrated that synthetic peptides spanning this region (including 172–191, 176–191, 177–191, and 178–191) produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin in normal rats, and reduced insulin sensitivity in intravenous insulin tolerance tests at a single dose of 5 nmol/kg body weight. The peptide must contain a minimum informational sequence (at least through amino acid 178) in correct physical configuration to be biologically active — fragments 179–191 and 180–191 were inert. In vitro research has explored the peptide's binding affinity to breast cancer-associated receptor proteins, suggesting potential for enhancing doxorubicin binding to tumor targets when co-loaded in chitosan nanoparticles. The peptide is also categorized in recent reviews as a GH fragment (alias AOD9604) used in online self-administration protocols purportedly to modulate the GH-IGF-1 axis.
Class: Growth hormone (GH) C-terminal fragment / synthetic peptide
Administration & storage
- Administration
- In vivo administration in rats (route not explicitly specified in abstract) (PMID: 645904)Intracellular/in vitro delivery via chitosan nanoparticles in MCF-7 cell line experiments (PMID: 35783198)
- Storage
- No storage conditions for HGH Fragment 176-191 are described in any of the reviewed abstracts.
- Cautions
- Animal data (rat) indicate that hGH 176-191 reduced insulin sensitivity at a single dose of 5 nmol/kg; potential dysglycemic effects in humans are unknown.,A recent narrative review flags this compound (AOD9604) among peptides associated with endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms, and injection-site reactions when used in unregulated self-administration contexts.,No regulatory approval exists for physique- or performance-related indications; product composition, dose, and purity in unregulated supply chains are uncertain.,Biologically plausible but unproven mitogenic concerns have been raised for GH-axis modulating peptides as a class.,Sterile technique is essential for any injectable compound to prevent infection — this is a universal self-evident caution not specific to this peptide.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Metabolic / glycemic effects (blood glucose and insulin modulation) Animal studies only
- Synthetic hGH 176-191 peptide produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin in normal rats. A single dose of 5 nmol/kg body weight significantly reduced insulin sensitivity in intravenous insulin tolerance tests. PMID 645904 Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978.
- Enhancement of anticancer drug delivery / oncology (in vitro, nanoparticle co-loading with doxorubicin) In vitro only
- In silico molecular docking suggested hGH fragment 176-191 can enhance doxorubicin binding to multiple breast cancer protein targets. Dual-loaded chitosan nanoparticles (hGH 176-191 + doxorubicin) demonstrated greater anti-proliferative activity against MCF-7 breast cancer cells than doxorubicin-loaded chitosan alone. PMID 35783198 Habibullah MM et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022.
- Performance enhancement / body recomposition (GH-IGF-1 axis modulation) Human observational
- Narrative review identifies hGH 176-191 (alias AOD9604) as among the peptides most commonly encountered in online self-administration protocols for performance enhancement, but notes absence of regulatory approval for physique- or performance-related indications and significant uncertainty around efficacy and safety. T PMID 42395176 Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol. 2026.
Safety signals
- Hyperglycemia: short-lived rise in blood glucose observed in rats following administration of hGH 176-191 PMID 645904
- Reduced insulin sensitivity: single dose (5 nmol/kg) significantly reduced insulin sensitivity in rat intravenous insulin tolerance tests PMID 645904
- Sustained rise in plasma insulin observed in rats following hGH 176-191 administration PMID 645904
- Class-level adverse effects reported for GH-axis peptides used in unregulated self-administration: endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions PMID 42395176
- Uncertainty around product composition, dose, and stacking practices in unregulated supply chains raises additional unknown safety risks PMID 42395176
Contraindications
- No specific contraindications are explicitly stated for HGH Fragment 176-191 in the reviewed abstracts. The narrative review notes absence of regulatory approval for performance/physique indications and cautions against off-label use generally for this class of peptides. PMID 42395176
Protocol
500 mcg subcutaneous injection, once daily, fasted (morning). Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not explicitly stated in abstract (in vivo rat study) | 5 nmol/kg body weight (single dose) | Single administration; blood glucose and insulin measured over time | animal | Research PMID 645904 |
| subcutaneous injection | 500 mcg | once daily, fasted (morning) · 8-12 weeks | biohackers and bodybuilders seeking fat loss without full HGH side effects | [Community] |
| subcutaneous injection | 250 mcg | once daily, fasted (morning) · 8-12 weeks | beginners or those sensitive to peptides seeking fat loss with lower cost outlay | [Community] |
| subcutaneous injection | 500 mcg | twice daily (morning fasted + pre-workout or pre-bed) · 8-12 weeks | experienced biohackers and bodybuilders in aggressive cutting phases | [Community] |
| subcutaneous injection | 1000 mcg | once daily, fasted (morning) · 8-12 weeks | advanced users and competitive bodybuilders seeking maximal fat loss | [Community] |
| subcutaneous injection | 500 mcg | once daily, 30 minutes pre-workout (fasted) · 8-12 weeks | biohackers and bodybuilders pairing peptide with fasted training sessions | [Community] |
| subcutaneous injection | 500 mcg | once daily at bedtime (fasted, 2+ hours post last meal) · 8-12 weeks | biohackers preferring nocturnal dosing to align with natural GH pulse | [Community] |
| subcutaneous injection | 500 mcg | once daily, fasted (morning) · 8-12 weeks | biohackers stacking HGH Frag 176-191 with CJC-1295/Ipamorelin for synergistic GH secretion and fat loss | [Community] |
| subcutaneous injection | 500 mcg | once daily, fasted (morning) · 8-12 weeks | biohackers stacking HGH Frag with AOD-9604 for additive lipolytic effect | [Community] |
| subcutaneous injection | 500 mcg | twice daily (morning fasted + pre-bed fasted) · 12-16 weeks | experienced bodybuilders in extended cutting or contest prep phases | [Community] |
| subcutaneous injection | 250 mcg | twice daily (morning fasted + pre-bed fasted) · 8-12 weeks | cost-conscious biohackers seeking twice-daily dosing at lower per-injection cost | [Community] |
All studies (3)
- PMID 42395176 Human observational
Performance enhancement / body recomposition (GH-IGF-1 axis modulation) - PMID 645904 Animal studies only
Metabolic / glycemic effects (blood glucose and insulin modulation) - PMID 35783198 In vitro only
Enhancement of anticancer drug delivery / oncology (in vitro, nanoparticle co-loading with doxorubic
Frequently asked
What is HGH Fragment 176-191 and what is it used for?
HGH Fragment 176-191 (also called AOD9604) is a synthetic peptide corresponding to amino acids 176–191 of the C-terminal region of human growth hormone. In a 1978 rat study, it produced a short-lived rise in blood glucose and a sustained rise in plasma insulin, and reduced insulin sensitivity. It has been studied in vitro as a potential enhancer of anticancer drug delivery when co-loaded in chitosan nanoparticles. It is also widely encountered in online self-administration protocols marketed for performance enhancement and body recomposition, though a 2026 narrative review notes no regulatory approval for these indications and significant uncertainty about efficacy and safety.
What dose of HGH Fragment 176-191 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the only dose reported in the reviewed published literature is 5 nmol/kg body weight as a single dose in rats. No human dosing data from clinical trials is available in the reviewed abstracts.
Is HGH Fragment 176-191 safe for human use?
The reviewed abstracts do not establish a human safety profile. Animal data show it reduced insulin sensitivity and caused hyperglycemia and elevated insulin in rats at 5 nmol/kg. A 2026 narrative review flags this compound class as associated with endocrine/metabolic disturbances, fluid retention, musculoskeletal symptoms, and injection-site reactions in unregulated self-administration settings, and raises unproven mitogenic concerns. No human clinical safety data are available in the reviewed literature. Please consult a licensed healthcare provider.
Can I stack HGH Fragment 176-191 with other peptides like GHRP-6 or CJC-1295?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: HGH Fragment 176-191 has only been studied alone in rats and in vitro in nanoparticle formulations. A narrative review notes that stacking practices in unregulated supply chains add significant uncertainty around safety.
Where can I buy HGH Fragment 176-191?
I don't recommend vendors or sources. Please consult a licensed provider.
Does HGH Fragment 176-191 help with fat loss?
I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly. The reviewed abstracts do not contain human evidence supporting fat loss effects. The peptide is encountered in online self-administration protocols for body recomposition, but no regulatory approval exists for such indications and efficacy is unproven.
Does HGH Fragment 176-191 affect blood sugar or insulin?
Yes, in animal research. A 1978 study in normal rats found that hGH 176-191 produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin. A single dose of 5 nmol/kg body weight also significantly reduced insulin sensitivity in intravenous insulin tolerance tests. Whether this translates to humans is unknown from the reviewed literature.
Can HGH Fragment 176-191 treat cancer?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What the reviewed research shows is limited to in vitro findings: an in silico and cell-line study found that hGH 176-191 co-loaded with doxorubicin in chitosan nanoparticles showed greater anti-proliferative activity against MCF-7 breast cancer cells than doxorubicin alone. This is very early-stage research and does not establish clinical utility.
Is HGH Fragment 176-191 approved by the FDA or other regulatory agencies?
The reviewed abstracts do not explicitly state the current regulatory status of HGH Fragment 176-191 with any agency (FDA, Health Canada, WADA). A 2026 narrative review notes that peptides in this class, including AOD9604, lack regulatory approval for physique- or performance-related indications. Manual verification with official regulatory sources is required for a definitive answer.
How should HGH Fragment 176-191 be stored or reconstituted?
The reviewed published abstracts do not provide reconstitution, preparation, or storage instructions for HGH Fragment 176-191 intended for human use. No storage conditions are described in the available literature. Please consult a licensed provider or compounding pharmacist.